Arca
Skip to content
Tools
Tools

HDAC2: Histone deacetylase 2

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Histone deacetylase that catalyzes the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on HDAC2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Vorinostat

Phase 30

    Phase 21

    • Mocetinostat

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      VorinostatApprovedMerck & Co. (MSD)Small moleculeInhibitorHistone deacetylase 2 inhibitor28—
      MocetinostatPhase 2Mirati Therapeutics Inc.Small moleculeInhibitorHistone deacetylase 2 inhibitor2—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
      NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabVorinostatPhase 2Not yet recruitingNew Approaches to Neuroblastoma Therapy Consortium2025-12-03
      Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett SyndromeVorinostatPhase 1RecruitingUnravel Biosciences, Inc.2025-09-02
      An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins SyndromeVorinostatPhase 1RecruitingUnravel Biosciences, Inc.2025-09-02
      Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) PopulationVorinostatPhase 2RecruitingSung Won Choi2025-05-29
      A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]VorinostatEarly phase 1RecruitingUniversity of Minnesota2024-11-18
      Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerVorinostatPhase 2RecruitingFred Hutchinson Cancer Center2023-11-24
      TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIVorinostatPhase 1 / Phase 2RecruitingTanja Andrea Gruber2023-05-08
      Venetoclax to Augment Epigenetic Modification and ChemotherapyVorinostatPhase 1RecruitingMedical College of Wisconsin2022-04-07
      Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent RhabdomyosarcomaMocetinostatPhase 1Active, not recruitingJonsson Comprehensive Cancer Center2020-03-06
      Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.MocetinostatPhase 1Active, not recruitingMemorial Sloan Kettering Cancer Center2017-07-18

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Neoplasm
      0.57
      Primary cutaneous T-cell non-Hodgkin lymphoma
      0.57
      Plasma cell myeloma
      0.56
      Neurodegenerative disease
      0.52
      T-cell non-Hodgkin lymphoma
      0.52
      Peripheral T-cell lymphoma, not otherwise specified
      0.52
      Mature T-cell and NK-cell non-Hodgkin lymphoma
      0.51

      Genes and Related Targets

      Complexes and families that share a gene with this target
      Genes
      HDAC2

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1937, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q92769, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.